This leaves little in the way of market incentives for manufacturers to develop vaccines, unless there are large numbers of people who are at risk in wealthy countries.
O que se traduce en  pouco interese no mercado para os fabricantes de vacinas, a menos que exista suficiente  demanda en países ricos.